Strongyloides-Ab ELISA
- Regulatory Status
- EU: CE
- Kit size
- 12 x 8
- Method
- ELISA
- Incubation time
- 1 x 1h, 1 x 30min, 1 x 15min
- Standard range
- cut-off index
- Specimen / Volumes
- 10µL Serum, Plasma
- Substrate / isotope
- TMB 450nm
About 30 million people in 70 countries, primarily in warmer climates, are infected with the roundworm Strongyloides stercoralis. Typical symptoms include serpiginous skin lesions, respiratory problems and atypical gastrointestinal complaints. Immunocompromised patients are at a particular risk because immunosuppression may precipitate a life-threatening hyperinfection syndrome with a mortality rate of over 80%.
Test methods include larval migration tests with stool samples or the detection of serum antibodies. Laboratory diagnosis is difficult because as many as 6 stool samples are often required to detect the larvae. Furthermore, conventional immunoassays display a high degree of cross-reactivity with other helminths. Test systems with high specificity are therefore of great importance in the diagnosis and therapy monitoring.
By using recombinant antigens, our ELISA for the determination of total antibodies against Strongyloides stercoralis allows for a significantly more specific antibody detection than conventional methods based on native antigens.
Evaluation of diagnostic performance
The assessment of diagnostic sensitivity and specificity was carried out using confirmed positive specimens (Cerba Specimen Services and INFORMM, Penang, Malaysia) as well as negative samples (blood bank) and sera that are potentially cross-reactive.
48 Strongyloides antibody negative samples
33 Strongyloides antibody positive samples
| Confirmed samples | |||
| Positive | Negative | ||
| Strongyloides Ab ELISA | Positive | 29 | 2 |
| Negative | 4 | 46 | |
Our Strongyloides Ab ELISA boasts a diagnostic sensitivity of 87.9% and specificity of 95.8%, and therefore fulfills the requirements of an effective diagnostic method for strongyloidiasis.
For concrete data please consult the Instruction for Use in the download box on the top right side.
Our Product Families
Our comprehensive immunoassay portfolio includes a number of specialty diagnostic immunoassays for endocrinology, immunology and autoimmunity, as well as for diagnosis of multiple infectious diseases. We are pioneers and market leaders in saliva diagnostics, with over 40 years of experience supplying a broad portfolio of luminescence- and ELISA-based tests, including our highly acclaimed HMGB1 and MuSK-Ab ELISAs.
And as experts in laboratory automation, we can support our customers with the protocols for open ELISA platforms, such as the Freedom EVOlyzer or Thunderbolt®.
All products are only available for sale to laboratory professionals and may not be available in all countries. Availability and regulatory status may vary across regions depending on local country-specific registration. Please always read and follow the instructions for use.
All of our assays have been designed and manufactured to meet the highest global regulatory requirements and quality standards. Tecan is certified under ISO 9001:2015, ISO 13485:2016 and is audited by a notified body according to Medical Device Single Audit Program (MDSAP).
This is who we are.
As part of the Tecan Group, we have a leading market position in diagnostics and research, with over 40 years of experience in the development, manufacture and supply of enzyme-, radiolabel- and luminescence-based immunoassays.
Our range of high-quality immunoassays is supported by a diverse portfolio of automated solutions, making us the perfect partner for you and your customers.
Happy to help.
At Tecan, we are driven to improve people’s lives and health.